arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ocugen, Inc.

OCGN
$0.81 ▼ -0.07 (-7.78%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
51 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Ocugen, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $274.3M
Dividend Yield —
Revenue Growth 8.4% ↗
Op. Margin —
ROIC 87.6% ↗
FCF / Share $-0.04 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity -0.10
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.49M
↑ +8.4% —
Net Income Profit after all expenses
$-19.18M
↓ -24.9% —
FCF / Share Free cash flow per share
$-0.04
↑ +2.2% —
Long-Term Debt Long-term obligations
$1.73M
↓ -92.9% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
100
Cash Quality →
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 51 quarters